LetroMed 2,5 mg MediPharma

Description

LetroMed 2,5 mg MediPharma — letrozole from MediPharma at 2.5 mg. Third-generation non-steroidal aromatase inhibitor — 2–5× more potent than anastrozole per mg. Reserved for heavy cycles or gynaecomastia reversal.

Key Benefits

• Most potent aromatase inhibitor in clinical use
• Reserved for aggressive E2 control or gyno rescue protocols
• 98%+ aromatase inhibition at standard doses
• Easy to over-suppress — titration with bloodwork essential
• Not a first-line on-cycle AI — anastrozole or exemestane preferred
• Each unit dosed at 5 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: 0.5–1.25 mg every other day for aggressive E2 management; 2.5 mg daily for 10–14 days for gyno rescue. Start low — letrozole crashes E2 fast. Bloodwork at 2 weeks mandatory.

How It Works

Non-steroidal aromatase inhibitor. Achieves ~98% aromatase inhibition at therapeutic doses (vs anastrozole ~85%). Reversible binding. Used clinically for breast cancer; off-label in AAS protocols for aggressive cycles or gyno reversal.

Pharmacokinetics

Plasma half-life approximately 2 days. Every-other-day or daily dosing depending on target. Steady-state in 10 days.

Potential Side Effects

Signature risk: crashed E2 with joint pain, libido loss, fatigue. Lipids can take a bigger hit than anastrozole. Use only when less potent AIs are insufficient.

Cycle & Stacking Guide

Reserved for aggressive E2 management or gyno rescue. Typical use: week 1–2 at 2.5 mg/day to reverse active gyno, then transition to anastrozole maintenance. Not a first-line on-cycle AI.

Manufacturer Notes

MediPharma produces to a standard European formulary pattern. Vial specs and carrier details are printed on every label.

Storage & Handling

Store in the original blister or bottle at 15–25 °C, away from direct sunlight, heat, and humidity. Oral preparations lose potency faster if exposed to moisture; keep the desiccant (if included) with the tablets. Keep out of reach of children. For research and educational purposes only.